Welcome to our dedicated page for Ambev SEC filings (Ticker: ABEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ambev S.A. filings document the reporting cycle of a Brazilian foreign private issuer with NYSE ADRs and B3-listed common shares. Form 20-F reports cover audited financial statements and annual business disclosure, while Form 6-K submissions furnish interim consolidated financial statements, quarterly operating results and current reports under Exchange Act rules for foreign issuers.
The filing record also covers beverage segment performance in Brazil Beer, Brazil NAB, Latin America South, Central America and the Caribbean, and Canada; capital allocation through interest on capital; treasury share activity; management and related-person securities transactions under Brazilian CVM rules; shareholder-meeting voting maps; board resolutions; committee matters; compensation; and other governance disclosures.
Ambev S.A. filed a 6-K stating that its Fiscal Council examined the independent auditor’s report, issued without qualification by Grant Thornton, and a performance report from the Chief Financial, Investor Relations and Shared Services Officer. The council expressed a favorable opinion on approving the Management Report, the financial statements for the year ended December 31, 2025, and the proposed allocation of net income, including dividends and interest on own capital as described in those statements.
Ambev S.A. reported 2025 fourth quarter and full-year results showing resilient profitability despite lower volumes. For 2025, total volume fell 3.3%, but organic net revenue rose 4.0% as net revenue per hectoliter increased 7.5%, supported by premiumization and revenue management.
Full-year Normalized EBITDA grew 5.6% to R$ 29.5 billion, with EBITDA margin up 50 bps to 33.4%, the third consecutive year of margin expansion. Profit increased 7.7% to R$ 15.99 billion and stated EPS grew 8.2%. Operating cash flow reached R$ 24.5 billion, and Ambev returned R$ 21.7 billion to shareholders on a cash basis, while ending 2025 with net cash of R$ 16.9 billion.
Ambev S.A. will pay the first tranche of interest on own capital to shareholders on April 6, 2026. The payment will be R$0.075 gross per share, which corresponds to R$0.063 net per share after Brazilian income tax.
The distribution was originally approved on December 9, 2025. Record dates remain December 18, 2025 for holders on B3 in Brazil and December 22, 2025 for holders on the NYSE, with shares and ADRs trading ex-IOC from December 19, 2025. The payment date for the remaining approved amount will be decided by the board by December 31, 2026.
Ambev S.A. filed a foreign issuer report stating that in January 2026 it did not carry out any transactions in its own securities or derivatives under the terms of Brazilian Instruction #44/2021. The company confirms its position in treasury shares, holding 145,113,436 common shares and no ADRs as of that reporting month.
Ambev S.A. reports transactions in its own securities by related parties for the period from January 1 to 31, 2026, under Brazilian Instruction 44/2021. The Board of Directors maintained holdings of 30,400,903 common shares and 468,040 ADRs, with no share movements in the month.
Management began the month with 5,822,022 common shares and 19,790 ADRs and ended with 5,208,794 common shares and 19,790 ADRs, reflecting a net decrease of 613,228 common shares after a series of sales, purchases, and securities lending operations mainly executed through XP Corretora and XP Investimentos S/A. The Fiscal Council held 2,500 common shares throughout the month with no transactions reported.
Ambev S.A. filed a 6-K/A detailing transactions in its own securities by board members, management, and fiscal council for the period from December 1 to 31, 2025, under Brazilian Instruction 358/2002.
For the board of directors group, common share holdings increased from 12,107,569 to 30,400,903 shares, with 468,040 ADRs unchanged, mainly through deliveries of restricted shares and an ownership transfer of 18,000,000 common shares. For management, common share holdings rose from 3,783,056 to 5,822,022 shares, with 19,790 ADRs unchanged, reflecting multiple deliveries of restricted shares directly by the company and several market sales executed via brokers BTG, Itaú, and XP, as well as a securities lending transaction in which management was the lender.
The fiscal council group reported no transactions during the month and maintained a balance of 2,500 common shares.
Ambev S.A. reports share and ADR movements by its board, management and fiscal council for the period from December 1 to 31, 2025, under Brazilian disclosure rules.
For the board of directors group, common share holdings rose from 12,107,569 shares to 30,400,903 shares, with 468,040 ADRs unchanged. Activity included deliveries of restricted shares directly from the company and an 18,000,000-share ownership transfer. Each ADR represents one common share.
For management, common share holdings increased from 3,783,056 to 5,927,946 shares, with 19,790 ADRs unchanged. Transactions combined deliveries of restricted shares from the company and sales of common shares through brokers BTG, Itaú and XP at prices mostly in the R$13–R$14 range. The fiscal council reported no trades, maintaining a balance of 2,500 common shares.
Ambev S.A. reported its December 2025 transactions in securities under Brazilian CVM Instruction 358. The company stated that the only transactions were deliveries of restricted shares made directly by the company using treasury stock. Ambev’s common share balance in treasury moved from 169,082,705 shares at the start of the month to 145,113,436 shares at month-end. Individual deliveries included, for example, 17,783,451 common shares on December 1 at R$13.86 per share, 5,938,658 shares on December 14 at R$14.02, and smaller deliveries on other dates.
Ambev S.A. reports that it will hold its ordinary shareholders' meeting on April 30, 2026. The company states this meeting is being called in line with applicable legislation and that additional details about the agenda and procedures will be provided closer to the date. This update is presented as a routine notice to shareholders from the Chief Financial and Investor Relations Officer.